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Abstract
We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently
powered to detect genome-wide significance (p,1.561027) for polymorphisms that modestly alter therapeutic warfarin
dose. The anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonary embolism,
and coronary malfunction. However, Caucasians vary widely (20-fold) in the dose needed for therapeutic anticoagulation,
and hence prescribed doses may be too low (risking serious illness) or too high (risking severe bleeding). Prior work
established that ,30% of the dose variance is explained by single nucleotide polymorphisms (SNPs) in the warfarin drug
target VKORC1 and another ,12% by two non-synonymous SNPs (*2, *3) in the cytochrome P450 warfarin-metabolizing
gene CYP2C9. We initially tested each of 325,997 GWAS SNPs for association with warfarin dose by univariate regression and
found the strongest statistical signals (p,10278) at SNPs clustering near VKORC1 and the second lowest p-values (p,10231)
emanating from CYP2C9. No other SNPs approached genome-wide significance. To enhance detection of weaker effects, we
conducted multiple regression adjusting for known influences on warfarin dose (VKORC1, CYP2C9, age, gender) and
identified a single SNP (rs2108622) with genome-wide significance (p= 8.3610210) that alters protein coding of the CYP4F2
gene. We confirmed this result in 588 additional Swedish patients (p,0.0029) and, during our investigation, a second group
provided independent confirmation from a scan of warfarin-metabolizing genes. We also thoroughly investigated copy
number variations, haplotypes, and imputed SNPs, but found no additional highly significant warfarin associations. We
present power analysis of our GWAS that is generalizable to other studies, and conclude we had 80% power to detect
genome-wide significance for common causative variants or markers explaining at least 1.5% of dose variance. These GWAS
results provide further impetus for conducting large-scale trials assessing patient benefit from genotype-based forecasting
of warfarin dose.
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Introduction
Warfarin is the most widely prescribed anticoagulant for
reducing thromboembolic events that often give rise to stroke,
deep vein thrombosis, pulmonary embolism or serious coronary
malfunctions [1]. A combination of genetic and non-genetic
factors cause Caucasians to exhibit 20-fold interindividual
variation in required warfarin dose needed to achieve the usual
therapeutic level of anticoagulation as measured by the prothrom-
bin international normalized ratio or INR [2–4]. Thus, in the
absence of information (genotypic, clinical, etc.) for predicting
each patient’s required warfarin dose, initial prescribed doses may
be too low (risking thrombosis) or too high (risking over-
anticoagulation and severe bleeding). Warfarin’s risk of serious
side effects, narrow therapeutic range, and wide interindividual
variation in warfarin dose have focused attention on the need to
better predict dose in the initial stage(s) of treatment.
We and others have shown that the warfarin drug target
VKORC1 (vitamin K epoxide reductase complex, subunit 1)
contains common polymorphisms that account for a major
portion (,30%) of the variance in required warfarin dose [5,6],
and we have recently evaluated ,1500 Swedish patients of the
Warfarin Genetics (WARG) cohort in the largest study to date
showing likely patient benefit from genetic forecasting of dose [3].
The study confirmed that SNPs in VKORC1 and in the warfarin-
metabolizing gene CYP2C9 (cytochrome P450, family 2, subfamily
C, polypeptide 9) predict ,40% of dose variance while non-
genetic factors (age, sex, etc.) jointly account for another ,15%.
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The robust and now widely replicated associations of warfarin
dose with VKORC1 and CYP2C9 have provided one of the most
successful applications of pharmacogenetics to date [7] and offer
promise for genetic predication of required dose in a clinical
setting [3].
Knowledge of major predictors of warfarin dose also impacts
the methodology for finding further dose-related genes. In early
candidate gene work with a small sample of 201 patients [8], we
noted that univariate regression (with tested SNP as the only dose
predictor) could statistically detect warfarin association with
VKORC1 and with one of two non-synonymous CYP2C9 SNPs
(*3) known to influence warfarin dose (Table 1 in [8]). However, a
second non-synonymous CYP2C9 SNP (*2) with known but
weaker influence on warfarin dose was not detected by univariate
regression, but *2 was statistically significant in multivariate
regression adjusted for the other known genetic and non-genetic
predictors of dose (Table 3 in [8]). These empirical results in a
small warfarin sample provided a signpost underscoring the
potential importance of multivariate regression for detecting weak
effects in studies now searching for additional warfarin genes
across the genome.
A genome-wide association study (GWAS) enables a systematic
search of the entire genome for genetic factors that cause any
inherited trait. This method has successfully identified susceptibil-
ity loci for common diseases [9], and is beginning to be applied to
pharmacogenomics. A recent warfarin GWAS in 181 patients did
not detect other genetic factors with major effects on warfarin dose
beyond VKORC1 [10] but was underpowered for identifying loci
with a moderate contribution. We have now genotyped 325,997
SNPs in 1053 patients of the WARG cohort and here report the
first GWAS that is sufficiently powered to detect additional genetic
factors that may only modestly influence warfarin dose.
Results
Figure 1A and the first line of Table 1 summarize results of
testing 325,997 GWAS SNPs for association with warfarin dose by
univariate regression. The strongest associations were at multiple
SNPs in and near VKORC1 (Figure 1A) with the lowest p-value
given by rs9923231 (P=5.4610278). In prior fine-mapping of the
VKORC1 locus [8], we identified rs9923231 as one of three SNPs
located in introns or immediately flanking VKORC1 that exhibit
almost perfectly concordant genotypes yielding pairwise linkage
disequilibrium (LD) r2<1 and which define the warfarin-sensitive
A-T-T haplotype at rs9923231-rs9934438-rs2359612 (see also
[11]). These highly concordant SNPs were the best predictors of
warfarin dose in our previous study and in this GWAS analysis
(p,5.4610278) and completely accounted for the dose variance
explained by all other fine-mapping SNPs near VKORC1 [8]. The
group of SNPs with the second lowest univariate p-values clustered
around CYP2C9 which contains two non-synonymous exonic
SNPs whose minor alleles (*2, *3) impair warfarin metabolism and
are well known to be associated with warfarin dose. In our
previous work [8], we discovered an unusual SNP (rs4917639)
whose minor allele is almost perfectly associated with the
‘‘composite’’ CYP2C9 allele formed by combining *2 and *3 into
a single allele. Indeed, the GWAS results (1053 subjects) confirmed
that LD is nearly perfect (pairwise r2<1.0) between rs4917639 and
the composite of *2 and *3. Thus, the highly significant univariate
result for rs4917639 (R2 = 0.121, p,3.1610231) reflects the
combined effect of CYP2C9*2 rs1799853 (R2 = 0.038,
p,8.8610213) and CYP2C9*3 rs1057910 (R2 = 0.080,
p,4.5610217). Figure 1A therefore indicates p-values for this
composite SNP as well as for *2 and *3.
Figure 1B and Table 1 (lines 2 to 5) show the results of
multivariate regression analysis in which individual SNPs were
tested for association with warfarin dose after adjustment for
established genetic and non-genetic predictors of dose. The only
SNP reaching genome-wide significance (p,1.561027) was a non-
synonymous SNP (rs2108622) in exon 2 of CYP4F2 (cytochrome
P450, family 4, subfamily F, polypeptide 2) introducing a Val to
Met amino acid change at position 433 (V433M). SNP rs2108622
predicts additional dose variance (,1.1%) that is independent of
the variance already explained by VKORC1 and CYP2C9. As noted
in the Introduction, our early studies with a small sample of 201
Swedish patients failed to detect the weak CYP2C9*2 effect on dose
by univariate regression but *2 was significant in multiple
regression [8]. The results in Table 1 with rs2108622 of CYP4F2
show the same phenomenon with a p-value of 1.661025 in
univariate regression (line 1) but progressively lower p-values as
known predictors are added to the multivariate model so that for
the full model a p-value of 8.3610210 is achieved which is far
below genome-wide significance (p,1.561027). The CYP4F2
association was further confirmed by testing an independent
replication panel of 588 Swedish warfarin patients who gave a
multivariate p-value of 0.0029 and a total overall p-value of
3.3610210 when combined with the GWAS subjects (Table 2).
During preparation of this paper, a candidate gene study of drug-
metabolizing and transporter genes independently discovered the
association of rs2108622 and CYP4F2 with warfarin dose,
providing further confirmation [12].
To increase the power of our multivariate regression model and
possibly detect additional weak effects, we added CYP4F2
(rs2108622) to the model as a predictor and conducted further
analyses. First, we retested the GWAS SNPs, but no new SNPs
reached genome-wide significance and there was also no apparent
excess of SNPs at lower significance thresholds (Figure S1). We
also tested warfarin association with haplotypes and with
ungenotyped SNPs imputed at 2.2 million HapMap SNPs, but
no haplotype or imputed SNP approached genome-wide signifi-
cance in a genomic region not containing VKORC1, CYP2C9 or
CYP4F2. To explore whether copy number variations (CNVs)
Author Summary
Recently, geneticists have begun assaying hundreds of
thousands of genetic markers covering the entire human
genome to systematically search for and identify genes
that cause disease. We have extended this ‘‘genome-wide
association study’’ (GWAS) method by assaying ,326,000
markers in 1,053 Swedish patients in order to identify
genes that alter response to the anticoagulant drug
warfarin. Warfarin is widely prescribed to reduce blood
clotting in order to protect high-risk patients from stroke,
thrombosis, and heart attack. But patients vary widely (20-
fold) in the warfarin dose needed for proper blood
thinning, which means that initial doses in some patients
are too high (risking severe bleeding) or too low (risking
serious illness). Our GWAS detected two genes (VKORC1,
CYP2C9) already known to cause ,40% of the variability in
warfarin dose and discovered a new gene (CYP4F2)
contributing 1%–2% of the variability. Since our GWAS
searched the entire genome, additional genes having a
major influence on warfarin dose might not exist or be
found in the near-term. Hence, clinical trials assessing
patient benefit from individualized dose forecasting based
on a patient’s genetic makeup at VKORC1, CYP2C9 and
possibly CYP4F2 could provide state-of-the-art clinical
benchmarks for warfarin use during the foreseeable future.
GWAS of Warfarin Dose
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detectable by the HumanCNV370 array might influence warfarin
dose, we used rigorous quality control and retained 879 samples
calling 2530 CNVs (see Materials and Methods). None of the
CNV loci were significantly associated with dose after correction
for multiple testing (lowest CNV p-value was 1.161024 which
exceeds 0.05/2530<2.061025). We note that probe density in
many of the detected CNVs is not optimal for conducting
association analyses and these results should therefore be viewed as
preliminary.
Finally, after excluding SNPs near VKORC1, CYP2C9 and
CYP4F2, we identified 40 other loci containing one or more
GWAS SNPs with p-values below 2.061024 and we genotyped 40
SNPs representing these loci in a follow-up sample of 588 Swedish
warfarin patients. However none of the 40 loci replicated for
association with warfarin dose, the lowest p-value being 0.04
which is not significant after correction for 40 tests (Table S1).
Having not found evidence for any additional genetic modulators
of dose, we examined the entire data set (GWAS plus followup
samples) for evidence of statistical interaction between pairs of the
established dose predictors (VKORC1, CYP2C9, CYP4F2, age, sex).
None of the pairs exhibited statistically significant interaction after
p-values were corrected for the 15 interaction tests (Table S2).
Figure 1. P-values for each GWAS SNP tested for association with warfarin dose. Horizontal axis shows SNP location and vertical axis is
2log10(p-value) for each SNP tested by univariate regression (A) or multivariate regression (B). Red dots and red lettering show SNPs and implicated
genes with p-values beyond the genome-wide significance threshold (1.561027) which is denoted by a horizontal line. (A) Univariate regression
shows genome-wide significant association to SNPs clustering near the warfarin drug target VKORC1 (e.g., P= 5.4610278, rs9923231) and near the
warfarin-metabolizing gene CYP2C9 (P= 4.5610217 for non-synonymous *3 SNP rs1057910, P= 8.8610213 for non-synonymous *2 SNP rs1799853,
P= 3.1610231 for *2*3 ‘‘composite’’ SNP rs4917639). (B) Multivariate regression adjusting for the contributions of VKORC1 and CYP2C9 had greater
power than univariate regression and detected genome-wide significant association to the CYP4F2 gene (P= 8.3610210, non-synonymous SNP
rs2108622).
doi:10.1371/journal.pgen.1000433.g001
Table 1. Association (p-value) of SNPs tested by univariate regression or multiple regression with progressive addition of known
dose predictorsa.
Predictors in regression analysis Tested SNP
VKORC1 CYP2C9*3 CYP2C9*2 CYP4F2 Distribution of all SNPs
rs9923231 rs1057910 rs1799853 rs2108622
None 5.4E-78 4.5E-17 8.8E-13 1.6E-05 Figure 1A
Age, sex 7.3E-97 1.2E-24 2.4E-14 4.8E-06 –
Age, sex, VKORC1 – 3.8E-43 1.0E-15 4.6E-07 –
Age, sex, VKORC1, CYP2C9*3 – – 1.4E-26 8.3E-08 –
Age, Sex, VKORC1, CYP2C9*3 and *2 – – – 8.3E-10 Figure 1B
aLinear regression on warfarin dose was calculated for the 1,053 GWAS subjects.
doi:10.1371/journal.pgen.1000433.t001
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We also performed a GWAS for a secondary trait (‘‘over-
anticoagulation’’) which we previously found was associated with
VKORC1 and CYP2C9 in a candidate gene study [3]. By titrating
warfarin dose, physicians attempt to achieve a target level of
anticoagulation determined by a reading of 2.0 to 3.0 for the
prothrombin international normalized ratio (INR), which is the
ratio of time required for a patient’s blood to coagulate relative to
that of a reference sample. However over-anticoagulation (defined
as an INR above 4.0) sometimes occurs and, using Cox regression,
our GWAS tested for SNP association with the occurrence of over-
anticoagulation in patients during the first 5 weeks of treatment
(see Materials and Methods: Association testing of SNPs and
haplotypes). We observed genome-wide significant association
(p,1.561027) at several SNPs in and around VKORC1 including
rs9923231 (P= 8.961029), but no other SNPs achieved genome-
wide significance including CYP2C9*3 (p,4.061025), CYP2C9*2
(p = 0.93), or the ‘‘composite’’ *2*3 SNP rs4917639 (p,0.007)
(Figure S2). However we note that our previous candidate gene
study evaluated a larger sample set (1496 WARG subjects) which
yielded genome-wide significant association with over-anticoagu-
lation for both VKORC1 rs9923231 (P=5.7610211) and
CYP2C9*3 (P=1.561029) [3]. To explore whether these SNPs
might cause over-anticoagulation independent of altering the
required (i.e., administered) warfarin dose, we added required dose
to the Cox regression model as a predictor of over-anticoagulation,
and found that both VKORC1 and CYP2C9*3 have a significant
effect independent of dose (P,0.05) (Table S3).
Discussion
We conducted the first GWAS sufficiently powered to detect
DNA variants with a modest influence on the warfarin dose
needed to achieve therapeutic anticoagulation. In univariate
analysis of GWAS SNPs (Figure 1A), we identified extremely
strong association signals (p = 10278 to 10213) at SNPs in and near
VKORC1 and CYP2C9, two genes already known to explain ,30%
and ,12% of warfarin dose variance, respectively. By applying
multivariate regression adjusting for known genetic and non-
genetic predictors of dose (Figure 1B), we also detected genome-
wide significance of p,8.3610210 at CYP4F2 (rs2108622) that
accounted for approximately 1.5% of dose variance. The
increased power of multivariate regression to detect this modest
effect is nicely illustrated in Table 1 which shows a higher
univariate p-value for CYP4F2 (p,1.661025) but progressively
lower multivariate p-values as known predictors of dose are added
to the regression model. We confirmed the CYP4F2 association in
a second large sample set and the association was also reported by
another group [12] during preparation of our work, thus fully
establishing the genuine effect of CYP4F2 (see also [10] where
CYP4F2 explained ,1% dose variance with nominal p,0.043
significance). Although multivariate regression has not been widely
used to increase power in other GWAS analyses because known
genetic variants usually explain little phenotypic variance, the
potential for power increase is perhaps obvious if known predictors
do explain substantial variance. Thus multiple regression has, for
example, been previously advocated for linkage analyses of line
crosses [13,14].
To estimate the multivariate regression power of our GWAS
(1053 subjects), we used Equation 1 (see Materials and Methods) to
calculate power to detect SNPs explaining specific magnitudes of
variance (R2test) for warfarin dose (see Table 3). The table shows
that power to achieve genome-wide significance (p,1.561027) is
essentially 100% for VKORC1 rs9923231 (R2test&0:28), CYP2C9*3
(R2test&0:08) and CYP2C9*2 (R
2
test&0:04), but power falls to
,48% for CYP4F2 rs2108622 (R2test&0:011). The table also shows
that when CYP4F2 is added to the multivariate model, a SNP
accounting for 1.5% or 1.0% of the dose variance would have
,82% or ,41% power of being detected, respectively. Therefore
we estimate that our GWAS had at least 80% power to detect
warfarin-associated variants explaining at least 1.5% of the dose
variance but 40% or less power to detect genome-wide significance
if a variant accounts for 1% or less dose variance.
However it is important to emphasize that these power
estimates assume that the dose-altering DNA variant is genotyped
and tested directly or is indirectly detected through a marker in
sufficiently high LD to the dose variant that the marker’s R2test
magnitude is detectable (Table 3). The assumption of directly
testing the dose-altering variant is accurate for CYP2C9*2 and *3
which are each known to alter warfarin metabolism [15,16] and is
likely correct for CYP4F2 rs2108622 which, like *2 and *3, changes
protein coding sequence. However, to explore whether other dose-
altering variants might be undetected due to insufficient LD with
genotyped GWAS SNPs, we determined the relationship between
Table 2. Multiple regression analysis of warfarin dose in the GWAS, replication and combined panels.
Predictor WARG GWAS (1053) Replication (588) Combined (1641)
Effect on doseb R2 P-value Effect on doseb R2 P-value Effect on doseb R2 P-value
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
VKORC1 rs9923231
(C-.T, 0.402)a
20.96 (21.03, 20.89) 0.283 1.6E-122 20.99 (21.09, 20.88) 0.284 5.0E-62 20.97 (21.02, 20.91) 0.283 2.7E-181
CYP2C9*3 rs1057910
(Ile359Leu, 0.070)a
21.13 (21.26, 21.00) 0.075 2.6E-55 21.08 (21.27, 20.89) 0.089 2.3E-26 21.11 (21.22, 21.00) 0.080 2.6E-79
CYP2C9*2 rs1799853
(Arg144Cys, 0.109)a
20.63 (20.74, 20.52) 0.048 1.7E-28 20.40 (20.55, 20.24) 0.023 5.5E-07 20.54 (20.63, 20.45) 0.038 1.1E-31
CYP4F2 rs2108622
(Val433Met, 0.240)a
0.25 (0.17, 0.33) 0.016 8.3E-10 0.16 (0.05, 0.27) 0.005 c0.0029 0.21 (0.14, 0.27) 0.011 3.3E-10
Age 20.04 (20.04, 20.03) 0.170 1.9E-63 20.03 (20.04, 20.03) 0.129 1.7E-31 20.04 (20.04, 20.03) 0.155 1.2E-111
Sex (male) 0.35 (0.25, 0.45) 0.017 7.6E-12 0.25 (0.10, 0.40) 0.009 0.001 0.30 (0.22, 0.38) 0.013 1.6E-12
aIn parenthesis are major/minor allele, and minor allele frequency.
bEffect of individual predictor on dose is indicated by regression coefficient and 95% confidence interval, proportion of explained variance (R2) and P-value.
cAssociation in same direction as GWAS was assessed by a one-tailed test.
doi:10.1371/journal.pgen.1000433.t002
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the variance observed at a marker (R2mrk) and at the causative
variant (R2cause) assuming pairwise LD of r
2 between the two
polymorphisms (see Materials and Methods: How Much Does
Linkage Disequilibrium Attenuate Association with a Quantitative
Trait?). The relationship is given by Equation 3 in Materials and
Methods (R2mrk&r
2R2cause) which is analogous to Pritchard and
Prezworski’s relationship (Ncause~r
2Nmrk) for the number of cases
(Ncause or Nmrk) providing equal power in a case-control study that
tests either the disease-causing SNP or a nearby marker [17]. To
use the equation R2mrk&r
2R2cause to estimate R
2
cause magnitudes for
variants that might be undetected by our GWAS, we note that
,90% of the GWAS SNPs had a minor allele frequency (MAF)
above 10% in our warfarin subjects implying that a ‘‘rare’’ dose-
altering variant (MAF<1%–5%) would be covered at a likely
maximum r2 of only ,0.1 to ,0.5. This low r2 coverage implies
that rare variants could have R2cause values (0.05 to 0.02) easily
detected by regression testing of the variant itself, but unlikely to
be detected through a GWAS marker since maximum R2mrk values
could drop to 0.01 or much lower (see Equation 3 and Table 3). By
contrast, ‘‘common’’ SNPs (MAF$5%), which might also be dose
variants, are covered by GWAS SNPs of this study at reasonably
high r2 values in most instances (r2.0.8 or r2.0.5 for ,60% or
,80% respectively of common SNPs [18] and r2.0.9 for ,90%
of non-synonymous common SNPs [19] in HapMap Caucasians).
We therefore conclude that our GWAS probably detected most
common SNP variants explaining 1.5% or more of the warfarin
dose variance, but may have failed to detect rarer variants that
could individually explain up to 5% of dose variance. We further
note that the HumanCNV370 array used in this study does not
have the required marker complement to undertake a compre-
hensive GWAS of common CNVs.
As noted in the Introduction, the widely replicated warfarin dose
associations with VKORC1 and CYP2C9 represent one of the most
successful applications of pharmacogenetics to date. Our study
together with that of Caldwell et al. [12] now also clearly
demonstrates that CYP4F2 (rs2108622) is a third gene that
influences warfarin dose, but our GWAS and statistical analysis
also implies that additional common SNP variants that influence
dose may not exist in Caucasian populations. However, Caucasians
might carry common variants with effects smaller than CYP4F2 or
rare variants whose effects are substantially larger than the,1% of
dose variance explained by CYP4F2. Furthermore, other uniden-
tified genes may influence warfarin dose in other ethnicities such as
Asians or Africans, and some rare dose-altering variants in known
genes such as VKORC1 may exist in only a subset of populations of
European descent [20]. Hence, future research could address ethnic
differences in the genetic variants that influence warfarin dose as
well as subtle intra-ethnic differences and admixture that may exist
in European or other populations.
In a recent study [3], we highlighted the potential benefit of pre-
treatment forecasting of required warfarin dose based on patient
genotypes at VKORC1 and CYP2C9 together with non-genetic
predictors of dose. Indeed, in August 2007, the US Food and Drug
Administration (FDA) updated warfarin labeling to recommend
initiating lower warfarin dose in some patients based on VKORC1
and CYP2C9 genotypes. However this recommendation is not a
requirement due to a lack of large trials demonstrating warfarin
patient benefit from dose forecasting (though two small trials
[21,22] do support such benefit; see also [23–27] for reviews and
other trials). The results of our GWAS provide further impetus for
conducting large-scale dose-forecasting trials by identifying
CYP4F2 as a third genetic predictor of dose and also by showing
that additional major genetic predictors may not exist in
Caucasians or may not emerge in the near-term. Hence, large-
scale trials of patient benefit from dose forecasting based on
VKORC1 and CYP2C9 (with possible inclusion of CYP4F2 as a
minor predictor) are likely to provide state-of-the-art clinical
benchmarks for warfarin use during the foreseeable future.
Materials and Methods
Subjects and Clinical Data
The study subjects were 1053 Swedish patients collected for the
WARG study [3] (http://www.druggene.org/). This is a multi-
centre study of warfarin bleeding complications and response to
warfarin treatment [28]. Anticoagulant response is measured by
INR, which is the ratio of the time required for a patient’s blood to
coagulate relative to that of a reference sample. By titrating
warfarin dose, physicians aim for a therapeutic INR reading
between 2.0 and 3.0; thus the primary quantitative outcome for
the GWAS was the mean warfarin dose (mg/week) given to a
patient during a minimum series of three consecutive INR
measurements between 2 and 3 [3]. As a secondary GWAS
outcome, we also catalogued each patient for the occurrence or
non-occurrence of ‘‘over-anticoagulation’’ during the first 5 weeks
of treatment (defined as an INR reading above 4.0) and tested for
genetic association which adjusted for the treatment day (1 to 35)
of the over-anticoagulation event (see ‘‘Association testing’’ below).
Table 3. Power to detect a dose-altering SNP as a function of its contribution to dose variance (R2) and adjustment by other
predictors in the multiple regression modela.
Predictors adjusted in multiple regression Tested SNP
VKORC1 CYP2C9*3 CYP2C9*2 CYP4F2 Unknown Unknown
description total rs9923231 rs1057910 rs1799853 rs2108622 SNP of SNP of
R2 (R2 = 0.283) (R2 =0.080) (R2 =0.038) (R2 =0.011) R2 =0.015 R2 = 0.010
None 0.000 1.00 1.00 0.88 0.03 0.10 0.02
Age, sex 0.168 1.00 1.00 0.96 0.06 0.19 0.04
Age, sex, VKORC1 0.452 – 1.00 1.00 0.26 0.56 0.19
Age, sex, VKORC1, CYP2C9*3 0.532 – – 1.00 0.40 0.73 0.31
Age, Sex, VKORC1, CYP2C9*3 and *2 0.570 – – – 0.48 0.81 0.39
Age, Sex, VKORC1, CYP2C9*3 and *2, CYP4F2 0.580 – – – – 0.82 0.41
aPower calculations assumed a sample size of 1,053 subjects and significance level of 1.5E-7 as employed in our GWAS.
doi:10.1371/journal.pgen.1000433.t003
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The clinical data collected by the WARG protocol included
gender and age since each is a known non-genetic predictor of
warfarin dose but did not include bodyweight and dietary
information (e.g. vitamin K intake). Regression analysis of
prescribed medication which can potentiate or inhibit warfarin
action was not a statistically significant predictor of warfarin dose
in the 1053 WARG GWAS subjects and hence was not included
as a predictor variable in the multivariate regression analyses. The
WARG study samples were previously described elsewhere
[3,4,28,29] as were the Uppsala followup samples [8]. The
WARG and Uppsala studies received ethical approval from the
Ethics Committee of the Karolinska Institute and the Research
Ethics Committee at Uppsala University, respectively.
Genotyping of SNPs and Sample Quality Control
From approximately 1500 WARG samples [3] examined for
non-degradation and appropriate concentration of DNA
(,50 ng/ml), we randomly selected 1208 subjects for genotyping
SNPs and CNV probes using the HumanCNV370 BeadChip
array (Illumina). We excluded SNPs with MAF below 1%, call rate
below 95%, or if call rate fell below 99% when MAF was below
5%. SNPs that departed from Hardy-Weinberg equilibrium
(P,1026) were also excluded. Subjects with genotyping call rate
below 95% were also eliminated. Using iPLEX (Sequenom),
subject identity (and associated phenotypic data) was cross-
checked by genotyping four gender markers and 47 SNPs also
carried on the HumanCNV370 array, enabling us to exclude
,136 misidentified subjects. Sample quality (contamination) was
further assessed by plotting each subject’s genome-wide heterozy-
gosity and eliminating outliers (with heterozygosity above or below
the range of 0.312–0.372). After these quality control steps, a total
of 1053 warfarin patients and 325,997 GWAS SNPs were retained
for analysis. The GWAS SNPs included two SNPs not on the
HumanCNV370 array but which are highly predictive of warfarin
dose [rs9923231 (VKORC1) and rs1799853 (CYP2C9*2)] which we
genotyped by TaqMan assay (Applied Biosystems).
Defining CNV Regions
Although we retained 325,997 GWAS SNPs for association
testing of SNPs, it should be noted that all,370,000 probes on the
Human CNV370 array were used to define CNVs. Log R ratio
values of probes were output from the BeadStudio software [30]. A
loess correction was applied to each sample to remove local
correlations or genomic wave [31]. The resultant genomic copy
number profiles were then segmented using Circular Binary
Segmentation [32]. Some samples displayed abnormally high
numbers of segments indicating problems in DNA quantity or
quality or hybridization. Samples were removed until the number
of segments across all samples was approximately normal. Using
this technique, 143 (14%) of samples were flagged as problematic.
These samples were excluded when CNV regions were defined but
included for association testing. Putative CNV were defined from
segments by applying a threshold on the segment log R ratio. This
threshold was asymmetric allowing for a differing response for
deletions and duplications. The central peak of the segment log R
ratio distribution was fitted and the threshold values obtained by
taking values at 65 standard deviations from the centre.
In order to define regions for association testing, merging of
CNV across samples was performed. This was achieved by
merging two putative CNV into a region if there was greater than
40% reciprocal overlap. This procedure defined 2530 CNV
regions in total. Of these, most were singletons (54%) or low
frequency, ,3% (93%), while 820 (70%) of the non-singleton
regions overlapped CNVs from the Database of Genomic Variants
[33]. We tested all 2530 CNVs for association, because a CNV
discovered as a ‘‘singleton’’ might well include multiple copies of a
rare CNV allele in the study samples.
Association Testing of SNPs and Haplotypes
At each SNP, genotypes were coded 0, 1 or 2 and the SNP was
tested for association with the square root of warfarin dose [8] by
either univariate or multivariate linear regression analysis con-
ducted in PLINK [34] (http://pngu.mgh.harvard.edu/,purcell/
plink/) or in R software (http://www.r-project.org/). We used the
same regression analysis to test association with all HapMap SNPs
not on the HumanCNV370 array by imputing ,2.2 million SNPs
using Beagle software [35] trained from genotypes of the 60
HapMap CEU parents [36]. We excluded SNPs whose imputed
MAF was below 5% or differed by more than 5% with MAF of the
CEU parents.
We also tested haplotypes for association with warfarin dose by
two approaches: (1) each subject’s warfarin dose residual
(difference between observed and predicted dose based on the
full multivariate regression model containing CYP4F2) was
considered a quantitative trait value and tested for association
with haplotypes defined across the genome in sliding windows of 2,
3 or 4 consecutive SNPs as implemented by PLINK software; (2)
by scanning GWAS genotypes, Beagle software groups genetically
related haplotypes into clusters which it then resolves into diallelic
(SNP-like) ‘‘pseudo-markers’’ optimized for detecting phenotypic
association. To test haplotypes, we evaluated the pseudo-marker
genotypes of warfarin patients at 1.97 million pseudo-markers
covering the genome by testing each pseudo-marker in the same
multivariate regression framework used to test individual SNPs (as
described in the preceding paragraph).
We tested for statistical interaction in modulating warfarin dose
for each pair of established dose predictors (VKORC1 rs9923231,
CYP2C9*2 and *3, CYP4F2 rs2108622, Age, Sex) using multivar-
iate regression and R software as described above. An interaction
term formed by multiplying the pair of predictor variables was
added to the multivariate regression equation which contained
only main effects of the 6 predictors, and standard ANOVA
compared this main-effect model with the enhanced interaction
model by testing for a statistically significant increase in explained
dose variance. Interaction test p-values were considered statisti-
cally significant if below the Bonferroni cutpoint determined by
correcting for the 15 interaction tests (i.e. p,0.0033<0.05/15).
To test for association with over-anticoagulation (INR.4.0)
during treatment days 1–35, we performed Cox proportional
hazard regression on survival time (day of over-anticoagulation)
using the survival library of R software. The GWAS data set of
1053 WARG subjects contained 215 subjects whose INR
exceeded 4.0 during days 1–35 while the entire dataset of 1489
WARG subjects contained 312 such subjects.
Association Testing of CNVs
For each CNV locus, association was tested with square root of
warfarin dose by multivariate regression analysis in which subject
copy number intensity was the CNV predictor of dose. This analysis
differs from association testing with SNP genotypes since the two
CNV alleles on homologous chromosomes generate one copy
number intensity rather than a separate allele for each chromosome.
As a QC strategy, we determined each subject’s rank in the dataset
for copy number intensity at each CNV on chromosome 17. This
enabled us to differentiate the majority of subjects (whose individual
distribution of ranks were approximately random and uniform)
from 174 obvious outliers due to poor quality DNA (whose ranking
distributions were ‘‘U-shaped’’ since their intensities strongly
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clustered at both high and low ranks). These 174 subjects were
excluded from the primary CNV association analysis (with further
confirmation of lower quality DNA for these subjects being their
rough correspondence to the subjects with lower (,99%) SNP call
rates). However, we also crosschecked the primary CNV analysis by
conducting association testing on the dataset without excluding the
174 subjects and found no statistically significant association with
warfarin dose at any CNV whether the dataset excluded or included
the subjects. Association testing of the CNVs was executed using R
software [37].
Replication of CYP4F2
For the replication of CYP4F2 rs2108622, we genotyped a panel
of 588 warfarin patients consisting of 410 subjects from the
WARG cohort [3] and 178 from the Uppsala cohort [38]. Table 2
shows regression on this pooled sample of 588 subjects. Separate
results for each of the two panels are given in Table S4.
Follow-Up of Moderately Significant SNPs
To possibly identify SNPs with genuine but weak associations to
warfarin dose, we excluded VKORC1, CYP2C9, CYP4F2 and
identified 40 other GWAS loci for follow-up genotyping exhibiting
multivariate regression p-values below 0.0002, and selected 40
SNPs representing these loci for genotyping. Only genotyped (not
imputed) SNPs were chosen for follow-up. We genotyped the same
558 patients as in the CYP4F2 replication using the iPLEX
MassARRAY.
Power Calculation
Suppose multiple regression analysis is conducted in N total
samples by testing a SNP with coefficient of determination (i.e.,
explained variance) R2test after adjustment for known predictors
whose total of coefficient of determination is R2knw. The probability
(power) to detect the tested SNP at a significance level a equals:
ð?
c
F ’ 1,N{2,NR2test

1{R2knw{R
2
test
  
dx, ð1Þ
where F9(1, N–2, h2) is the probability density function for an F
distribution with 1, N-2 degrees of freedom and non-centrality
parameter h2 (Section 28.28 in [39], Example 8.4 in [40]). Here
the constant c satisfies the equation:
a~
ð?
c
F 1,N{2ð Þ dx, ð2Þ
where a is the significance level, and F(1, N–2) is the probability
density function for a F-distribution of degree of freedom one and
N–2.
How Much Does Linkage Disequilbrium (LD) Attenuate
Association with a Quantitative Trait?
Association with a quantitative trait (QT) becomes weaker for a
marker SNP in LD with a SNP that alters the QT, and hence the
association becomes more difficult to detect at the marker than at
the QT-altering SNP. Here we quantify the LD attenuation for a
QT when testing for association by linear regression (which
includes the Cochran-Armitage trend test for dichotomous traits),
and we obtain a result analogous to the LD attenuation for the
Pearson Chi-square test for allelic association to dichotomous traits
as in cases and controls [17]. If a causative QT-altering SNP has a
coefficient of determination (i.e., explained variance) R2cause and is
in pairwise LD of r2 with a marker SNP, then the coefficient of
determination for the marker SNP (R2mrk) is approximated by:
R2mrk&r
2R2cause ð3Þ
In other words, when testing a marker, the proportion of
explained variance decreases by a factor of r2.
To begin the proof of Equation 3, let the QT be represented by
the random variable ‘‘q’’, and let ‘‘m’’ and ‘‘x’’ be SNP genotypes
(coded 0, 1, or 2) representing the marker and causative (QT-
altering) SNP, respectively. The coefficients of determination
R2mrk and R
2
cause are equal to the square of two correlation
coefficients (denoted by ‘‘Corr’’) measuring the correlation of m
or x with q:
R2mrk~Corr m,q½ 2 ð4Þ
R2cause~Corr x,q½ 2 ð5Þ
Also note that correlation between genotypes at the marker and
causative SNP is given by another correlation coefficient:
R2geno~Corr m,x½ 2 ð6Þ
It is well known that the partial correlation coefficient of m and q
conditioned on x is (equation 16.20, p. 649 in [41]):
Corr m,q xj½ ~ Corr m,q½ {Corr m,x½ Corr x,q½ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{Corr m,x½ 2
 
1{Corr x,q½ 2
 r ð7Þ
However, conditional on genotype at the causative SNP, marker
m and the QT q would be uncorrelated (assuming m is not in LD
with a second causative polymorphism) and thus the numerator of
Equation 7 would be zero implying that:
R2mrk~R
2
genoR
2
cause ð8Þ
Based on prior work [42–44], we show in Text S1 that the
squares of the genotypic correlation coefficient R2geno and LD
correlation coefficient r2 are approximately equal if the population
is in Hardy-Weinberg equilibrium. Therefore, substituting r2 for
R2geno in Equation 8 gives Equation 3.
Supporting Information
Figure S1 QQ plot for association of each GWAS SNP with
warfarin dose. SNPs were tested for association with warfarin by
regression analysis that adjusted for age, sex, and genotype at
VKORC1, CYP2C9*2 and *3, CYP4F2. The QQ plot omits SNPs in
loci already known to be associated with warfarin dose (VKORC1,
CYP2C9, CYP4F2). The excess of SNPs with small p-values is
minor: whereas 65.4 SNPs with p,0.0002 are expected, 70 were
observed (1.069 times inflated).
Found at: doi:10.1371/journal.pgen.1000433.s001 (0.20 MB PDF)
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Figure S2 Manhattan plot of GWAS results of testing for
association with warfarin-induced over-anticoagulation. Horizon-
tal axis is the genomic position, and vertical axis is minus log of p-
value. Red dots above the gray line indicate association of
genome-wide significance (p,1.561027) at SNPs in the VKORC1
locus such as rs9923231 (p=8.961029). However, no other loci
achieved genome-wide significance. See main text for more details.
Found at: doi:10.1371/journal.pgen.1000433.s002 (0.07 MB PDF)
Table S1 Multivariate regression results for 40 SNPs followed-
up after GWAS. Unlike rs2108622 of CYP4F2, none of these 40
SNPs exhibited statistical significance after correction for multiple
testing. See main text for more details.
Found at: doi:10.1371/journal.pgen.1000433.s003 (0.03 MB
XLS)
Table S2 Testing for statistical interaction between predictors of
warfarin dose. After correcting for the 15 interaction tests, no pair
of predictors exhibited statistically significant interaction. Data is
for the combined panel of subjects (N= 1641). See main text for
more details.
Found at: doi:10.1371/journal.pgen.1000433.s004 (0.02 MB
XLS)
Table S3 Survival time analysis for incidence of over-anticoag-
ulation within the first 5 weeks of treatment in the whole WARG
cohort (N= 1489). See main text for more details.
Found at: doi:10.1371/journal.pgen.1000433.s005 (0.02 MB
XLS)
Table S4 Multiple regression analysis of warfarin dose in
WARG replication samples, WARG GWAS plus replication, or
Uppsala replication samples. This table shows the same results
displayed in Table 2 of the main text except that WARG and
Uppsala subjects are separated into different subsets.
Found at: doi:10.1371/journal.pgen.1000433.s006 (0.02 MB
XLS)
Text S1 For populations in Hardy-Weinberg Equilibrium,
Linkage Disequilibrium r2 and Genotypic R2 are approximately
equal.
Found at: doi:10.1371/journal.pgen.1000433.s007 (0.03 MB
DOC)
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